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AbstrAct
Objective Value frameworks in oncology have not 
been validated for the assessment of treatments in 
haematological malignancies, but to avoid overlaps and 
duplications it appears reasonable to build up experience 
on existing value frameworks, such as the European 
Society for Medical Oncology—Magnitude of Clinical 
Benefit Scale (ESMO- MCBS).
Methods Here we present the results of the first 
feasibility testing of the ESMO- MCBS v1.1 for 
haematological malignancies based on the grading of 
80 contemporary studies for acute leukaemia, chronic 
leukaemia, lymphoma, myeloma and myelodysplastic 
syndromes. The aims were (1) to evaluate the scorability of 
data, (2) to evaluate the reasonableness of the generated 
grades for clinical benefit using the current version and 
(3) to identify shortcomings in the ESMO- MCBS v1.1 that 
require amendments to improve the efficacy and validity of 
the scale in grading new treatments in the management of 
haematological malignancies.
Results In general, the ESMO- MCBS v1.1 was found 
to be widely applicable to studies in haematological 
malignancies, generating scores that were judged as 
reasonable by European Hematology Association (EHA) 
experts. A small number of studies could either not be 
graded or were not appropriately graded. The reasons, 
related to the differences between haematological and 
solid tumour malignancies, are identified and described.
Conclusions Based on the findings of this study, 
ESMO and EHA are committed to develop a version of 
the ESMO- MCBS that is validated for haematological 
malignancies. This development process will incorporate 
all of the usual stringencies for accountability of 
reasonableness that have characterised the development 
of the ESMO- MCBS including field testing, statistical 
modelling, evaluation for reasonableness and openness 
to appeal and revision. Applying such a scale will support 
future public policy decision- making regarding the value 
of new treatments for haematological malignancies and 
will provide insights that could be helpful in the design of 
future clinical trials.
IntROduCtIOn
In recent years, rapid developments in 
haematology research resulted in a consid-
erable expansion of treatment options. The 
development of instruments to measure clin-
ical benefit is essential in the current scenario 
where increasing numbers of treatments 
for haematological malignancies (HMs) are 
becoming available, often targeting a small 
and defined subpopulation of patients. 
Key questions
What is already known about this subject?
 ► The European Society for Medical Oncology—
Magnitude of Clinical Benefit Scale (ESMO- MCBS) 
v1.1 is a validated value scale for solid tumour on-
cology, but it has not yet been evaluated for the use 
in haematological malignancies.
What does this study add?
 ► Here, we present the results of the first feasibility 
testing of the ESMO- MCBS v1.1 for haematological 
malignancies based on grading of 80 contemporary 
studies for leukaemia, lymphoma, myeloma and my-
elodysplastic syndromes.
 ► The ESMO- MCBS v1.1 was found to be widely ap-
plicable to studies in haematological malignancies, 
generating scores that were judged as reasonable 
by European Hematology Association (EHA) experts; 
however, a small number of studies could either not 
be graded or were not appropriately graded because 
of shortcomings related to the differences between 
haematological and solid tumour malignancies.
How might this impact on clinical practice?
 ► Based on the findings of this study, ESMO and EHA 
are committed to develop a version of the score that 
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For this, several value frameworks have been published 
by different organisations and institutions taking into 
account or emphasising different aspects contributing 
to such an evaluation.1 These frameworks vary in terms 
of their definition of value, target audience and method-
ology, and each of them has specific limitations, which 
should be taken into consideration when interpreting 
their outputs.2 Until now, value frameworks developed in 
oncology have not been validated in the setting of HMs.
The European Society for Medical Oncology (ESMO) 
has developed such a value framework called the ESMO—
Magnitude of Clinical Benefit Scale (ESMO- MCBS).3 
Initially published in 2015, the scale is a validated and 
reproducible tool in solid tumour oncology with a partic-
ular focus on the clinical benefit. The ESMO- MCBS was 
developed to generate clear, valid and unbiased grading 
of the magnitude of clinical benefit demonstrated in 
therapeutic studies that could be used for a number 
of purposes including public health policy and health 
technology assessment (HTA), clinical decision- making, 
medical publication and journalism. The ESMO- MCBS 
grading highlights those treatments which substantially 
improve the duration of survival and/or the quality of 
life (QOL) of patients with cancer and aims to distin-
guish them from trials demonstrating more limited and 
sometimes even marginal benefits. The ESMO- MCBS 
was revised (version 1.1) in 2017, based on feedback 
and queries from clinicians, patients, researchers and 
representatives of the pharmaceutical industry, and a 
dynamic process of internal peer review.4 Version 1.1 
incorporates 10 revisions and most importantly allows 
also for scoring of single- arm studies. The ESMO- MCBS 
assigns categorical benefit scores to European Medicines 
Agency (EMA) approved drugs, based on results from 
‘positive’ randomised clinical trials: (1) superiority trials 
that have demonstrated a statistically significant result 
for the primary endpoint of the study, or secondary in 
case of overall survival (OS) and (2) non- inferiority 
trials, reaching a conclusion of non- inferiority. Primary 
or secondary endpoints included in the scoring system 
are OS, progression- free survival (PFS), QOL, treatment 
toxicity or response rates. In developing the ESMO- MCBS 
scale, ESMO aspired to meet standards for ‘account-
ability for reasonableness’,5 6 incorporating extensive 
field testing, statistical modelling7 and peer review of the 
‘reasonableness’ of the generated results into the devel-
opment process. The ESMO- MCBS is currently incorpo-
rated in ESMO’s clinical practice guidelines and is being 
used as part of HTA processes.8 9
The European Hematology Association (EHA) and 
ESMO have developed a joint initiative to develop a 
version of the ESMO- MCBS that is validated for HMs. As 
a first step in this process, we have field tested the current 
version of the ESMO- MCBS (version 1.1) across a wide 
spectrum of HMs. The aims of this evaluation were (1) to 
evaluate the scorability of data derived from contempo-
rary clinical trials in HMs, (2) to evaluate the reasonable-
ness of the generated grades for clinical benefit using the 
current version and (3) to identify shortcomings in the 
ESMO- MCBS v1.1 that require amendments to improve 
the efficacy and validity of the scale in grading new treat-
ments in the management of HMs.
MetHOds
study selection
The corresponding disease- oriented EHA scientific 
working groups identified experts who selected repre-
sentative treatments currently used in clinical practice 
with a focus on recently approved drugs and novel strat-
egies, to be evaluated for each of the common haema-
tological malignancies: acute lymphoblastic leukaemia 
(ALL), acute myeloid leukaemia (AML), chronic lympho-
cytic leukaemia (CLL), chronic myeloid leukaemia 
(CML), Hodgkin and non- Hodgkin lymphomas, multiple 
myeloma (MM) and myelodysplastic syndromes (MDS). 
The treatments selected underwent a literature search to 
identify corresponding clinical trials and data.
esMO-MCBs grading
Identified studies were graded by members of the EHA 
scientific working groups according to the ESMO- MCBS 
v1.1 forms4 in accordance with the instructions provided 
by ESMO. Magnitude of clinical benefit scores range 
from A to C for treatment strategies with curative intent 
and 5-1 for treatments with non- curative intent, with 
scores of A–B and 5-4 relating to a substantial level of 
clinical benefit. Initial grading by the expert groups were 
reviewed by the ESMO- MCBS working group for applica-
bility and correctness.
evaluations
For each disease entity, we evaluated the scorability of the 
evaluated studies and the reasonableness of the derived 
scores. Based on these findings, we identified shortcom-
ings in the current version of the ESMO- MCBS that either 
precluded scoring or which generated grading which was 
considered not to be a reasonable estimation of benefit 
when such studies were identified.
Results
The extensive research concluded in 80 studies, 5 of 
which had either more than two arms or different publi-
cations for the same trial presenting results after longer 
follow- up times (87 studies and/or comparisons in total). 
In detail, we have scored 7 studies for AML, 5 studies for 
ALL, 8 studies for CLL, 4 studies for CML, 23 studies for 
non- Hodgkin and Hodgkin lymphoma, 23 studies for MM 
and 10 studies for MDS. The ESMO- MCBS v1.1 tool was 
applied in all the 87 distinct studies and/or subgroups.
Acute myeloid leukaemia
Studies evaluated: Seven studies were evaluated,10–16 three 
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Scorability: All studies were published with endpoints 
and data applicable to the ESMO- MCBS v1.1.
Reasonableness: The separation of studies with curative/
non- curative intent corresponds closely to the distinction 
between intensive versus non- intensive chemotherapy 
regimens which are the terms usually applied in the treat-
ment of AML. Grading effectively distinguished between 
high benefit treatment strategies in a curative setting and 
stratified between higher and lower benefit treatments in 
a non- curative setting.
Shortcomings: None identified.
Acute lymphoblastic leukaemia
Studies evaluated: Five studies were evaluated,17–23 and 
these included studies relating to three agents recently 
approved by EMA for relapsed and refractory ALL 
(table 2).17–20 22
Scorability: Four of the five studies were published with 
endpoints and data applicable to the ESMO- MCBS v1.1. 
The only not scoreable study was the single- arm study of 
ponatinib as add- on to standard of care upfront treat-
ment with curative intent.21
Reasonableness: Both the first- in class bispecific antibody 
blinatumomab (TOWER trial)17 18 and the antibody- drug 
conjugate inotuzumab ozogamicin (INO- VATE trial)19 20 
reached high scores based on positive OS data and favour-
able QOL data for blinatumomab (ESMO- MCBS v1.1 
scores 5 and 4, respectively). The chimeric antigen 
receptor (CAR) T- cell treatment in children/young 
adults with relapsed or refractory B- cell ALL was graded 
with maximal credit of 3 for a single- arm study in a non- 
curative setting.22 The ponatinib treatment (single- arm 
PACE trial)23 was assigned grade 2 based on the major 
molecular response (MMR) in the non- curative setting.
Reasonableness: Grading effectively distinguished 
between high benefit treatment strategies in a curative 
stetting and stratified between higher and lower benefit 
treatments in a non- curative setting.
Shortcomings: One shortcoming was identified:
1. The ESMO- MCBS v1.1 does not have a form to grade 
single- arm treatments with curative intent. This short-
coming precluded scoring in one study21 and may also 
have been relevant to the grading of CAR T- cell salvage 
therapy which could also be considered as curative.22
Chronic lymphocytic leukaemia
Studies evaluated: Eight studies were evaluated (table 3).24–35
Scorability: CLL is generally a relatively indolent disease 
with a very long survival—often decades long—and many 
patients do not need intervention for many years and 
when treatment is initiated it commonly generates very 
long periods of remission. For these reasons, PFS is gener-
ally the most relevant and measurable primary endpoint. 
Since CLL is generally not considered to be a curable 
disease, all scoring was performed using scales for non- 
curative disease. One study27 could not be scored because 
the primary objective of non- inferiority with regard to PFS 
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subcohort of patients older than 65 years, which are rele-
vant for clinical practice (particularly in view of presented 
toxicity data) did not show non- inferiority and they were 
derived from a post hoc exploratory analysis.
Reasonableness: Overall scoring was considered reason-
able with the highest grades being achieved by studies 
demonstrating either mature OS data24–26 or PFS gains 
with long- term plateauing of PFS,33 or compelling PFS 
gains.28 29 Grading of the phase III study of ibrutinib versus 
ofatumumab (RESONATE trial)31 32 was considered to be 
low; it was credited for PFS advantage including gain in 
the tail of the curve but was penalised for toxicity associ-
ated with the more prolonged drug exposure in contin-
uous treatment (ESMO- MCBS v1.1 score 3). However, the 
9% improvement in OS at 12 months was not credited as 
these results are deemed immature by the ESMO- MCBS 
criteria. The benefit of novel agents in populations with 
high unmet need, like relapsed and refractory patients 
with CLL carrying deletion in chromosome 17 p, was 
graded reasonably using form 3 for single- arm studies in 
a non- curative setting.34 35
Shortcomings: One shortcoming was identified:
1. The EHA scientific working group members felt that 
compelling immature survival benefit ought to be 
credited even when the median survival of the control 
arm has not been reached.
Chronic myeloid leukaemia
Studies evaluated: Four landmark trials addressing the 
use of tyrosine kinase inhibitors imatinib, nilotinib, 
dasatinib and bosutinib upfront for chronic phase CML 
were graded.36–43 Only one of these had mature OS data 
(table 4).38
Scorability: CML is generally considered an incurable 
disease, but in a small proportion of cases with deep molec-
ular responses the disease may be eradicated. Thus, when 
mature survival data were available, CML was scored for 
both curative and non- curative intent.36–38 Contemporary 
studies in CML treatments are conventionally evaluated 
using molecular response evaluations.44 45 This differs 
from the concepts of ‘pathological complete response’ or 
‘response rate’ which are terms used in the ESMO- MCBS 
v1.1. Scoring of these studies was only possible by inter-
preting deep molecular responses (MMR 4–5) as patho-
logical complete responses (form 1) or major responses 
(form 2 c).39–43 In one study,36–38 PFS/event- free survival 
(EFS) gains could not be credited because the PFS of the 
control arm was very long and had not reached median 
PFS after 11 years of follow- up.
Reasonableness: In the IRIS study of imatinib versus 
former standard interferon plus cytarabine, initial scoring 
at 18 months was credited on the basis of complete cyto-
genic response for curative intent with a grade of C and 
improvement in molecular response rate with grade 
2.36–38 At 10- year follow- up, the imatinib scores B for cura-
tive intent based on survival improvement. While the 
grades for curative intent were considered reasonable, 
the EHA working group considered the ESMO- MCBS 
grade of 2 for non- curable intent to be too low for the 
benefits observed.
The remaining studies of nilotinib, dasatinib and bosu-
tinib show minor improvements in complete molecular 
response rates when compared with imatinib (grade 2) 
in a non- curative setting.39–43 None of these agents had 
mature data beyond 5 years and consequently they were 
not graded for curative intent.
Shortcomings: These relatively low scores for imatinib 
in the non- curative grading appear to indicate two short-
comings in the ESMO- MCBS v1.1:
1. When PFS (or EFS) is very long, there is no mechanism 
to credit strong interim gains when the median PFS of 
the control arm has not yet been reached.
2. The surrogacy of complete cytogenic response and level 
4–5 MMR, defined as 4 to 5- log reduction in BCR–ABL1 
transcript levels from a standardised baseline, are much 
stronger surrogates for survival than pathological com-
plete response and response rate in solid tumours.44 45 
Consequently, form 2 c needs to be amended to incor-
porate evaluation of deep molecular responses.
Indolent non-Hodgkin’s, relapsed/refractory setting of non-
diffuse large B-cell lymphoma (non-dlBCl) and Hodgkin’s 
lymphoma
Studies evaluated: Twelve studies of recently approved 
drugs for indolent non- Hodgkin’s, relapsed/refractory 
setting of non- DLBCL and Hodgkin’s lymphoma were 
evaluated (table 5).46–62
Scorability: In one of the studies,46 PFS/EFS gains could 
not be graded because the PFS of the control arm was very 
long, the median PFS was not reached and only interim 
gains were reported. The BRIGHT study could not be 
scored because form 2 c makes no provision for scoring 
of non- inferiority studies based on response rates.49 50 
The remaining 10 studies were published with endpoints 
and data applicable to the ESMO- MCBS v1.1 and were all 
evaluable.
Reasonableness: The grading was applicable and was 
judged by the EHA working group to be reasonable in the 
evaluated trials, endorsing relatively high benefit grades, 
that is, ESMO- MCBS v1.1. scores of 4–5 for 7 of the 10 
evaluable studies.
Shortcomings: Two shortcomings were observed:
1. The ESMO- MCBS v1.1 has no mechanism for scoring 
non- inferiority studies based on response rate.
2. When PFS (or EFS) is very long, there is no mechanism 
to credit strong interim gains when the median PFS of 
the control arm has not yet been reached.
diffuse large B-cell lymphoma
Studies evaluated: Eleven studies were evaluated63–75; two 
in the first- line setting with curative intent,63–66 two inten-
sified therapies for first- line and salvage setting, respec-
tively, with both curative and non- curative intent,67 68 two 
single- arm studies of CAR T- cell salvage therapy70 71 and 
five in a non- curative setting for relapsed and refractory 
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Scorability: All studies incorporated required data 
for evaluation using the ESMO- MCBS v1.1. Single- arm 
studies of CAR T- cell therapy for refractory or resistant 
disease70 71 could not be evaluated for curative intent. The 
NCIC- CTG LY12 trial could not be graded in the non- 
curative setting because non inferiority was evaluated on 
the basis of overall response rate.68
Reasonableness: The grading was applicable and was 
judged by the EHA working group to be reasonable in 
the evaluated trials, endorsing high benefit grades for 
first- line therapies with curative intent.63–67 Lower benefit 
scores for trials in the relapsed and refractory therapies 
were considered reasonable.
Shortcomings: One shortcoming was identified:
1. The ESMO- MCBS v1.1 does not have a form to grade 
single- arm treatments with curative intent and this 
shortcoming does not allow for the representation of 
the full potential benefit of CAR T- cell salvage thera-
py.70 71
Multiple myeloma
Studies evaluated: Table 7 describes results from eight 
studies in the first- line setting.76–84 Of these, three were 
conducted for autologous stem cell transplantation 
(ASCT) eligible76–78 patients and five are for ASCT ineli-
gible patients.79–84 Table 8 describes the results of a further 
15 studies with relapsed or refractory myeloma.85–104
Scorability: Most studies incorporated required data for 
evaluation using the ESMO- MCBS v1.1. The PETHEMA/
GEM study comparing VTD (bortezomib, thalidomide 
and dexamethasone) to TD (thalidomide and dexa-
methasone) or VBMCP/VBAD/B (vincristine, BCNU, 
melphalan, cyclophosphamide, prednisone/vincris-
tine, BCNU, doxorubicin, dexamethasone/bortezomib) 
as induction therapies did not report HRs for the PFS, 
resulting in precluded scoring with non- curative intent 
using form 2b.76 The GIMEMA 2005 study could not 
be scored for non- curative intent because the median 
PFS of the control arm had not yet been reached.77 The 
MM5 non- inferiority study78 could not be scored for 
non- curative intent because non- inferiority was based on 
response rate.
Reasonableness: First- line treatments for patients who 
are ASCT eligible are graded both for curative and non- 
curative intent. The relatively low grades of C for curative 
intent achieved in two of the ASCT eligible studies76 77 
reflect the prevailing consensus that MM is rarely cured. 
In most studies evaluated, the scale was feasible and the 
results were consistent with clinical practice.
Shortcomings: Three previously described shortcomings 
influenced scoring for a small number of these studies.
1. The ESMO- MCBS v1.1 has no mechanism for scoring 
non- inferiority studies in a non- curative setting based 
on response rate.
2. When PFS (or EFS) is very long, the ESMO- MCBS v1.1 
has no mechanism to credit strong interim gains when 
the median PFS of the control arm has not yet been 
reached.
3. The EHA working group members felt that the capita-
tion of PFS at a maximal preliminary grade of 3, with 
provision for an upgrade based on tail of the curve 
only if there is a plateau in the study medication PFS 
with gain of >10% at 12 months, may have undervalued 
some MM treatments.96 97 The plateau requirement for 
this adjustment precludes credit for substantial pro-
longed gains in PFS in this disease entity.
Myelodysplastic syndrome
Studies evaluated: Ten studies were evaluated in this 
setting.105–114 Of these, two studies were evaluated based 
on OS or PFS and the remaining eight studies were evalu-
ated based on response rate (table 9).
Scorability: All studies incorporated required data for 
evaluation using the ESMO- MCBS v1.1. Clinical benefit 
measure was, however, partly confounded by the hetero-
geneity of the available definitions of haematological 
response and their clinical meaningfulness.
Reasonableness: In the two studies evaluating 
hypomethylating agents in intermediate- risk/high- risk 
patients,105 106 the ESMO- MCBS v1.1 graded them with 
substantial benefit based on either PFS gain or OS gain 
with improved QOL. In lower risk patients, the remaining 
eight studies included randomised trials investigating 
erythropoietin- stimulating agents, lenalidomide in MDS 
with del(5q) or non- del(5q) and immunosuppressive 
therapy with antithymocyte globulin plus cyclosporine, 
compared with best supportive care.107–114 All studies 
were evaluated based on response rates, but they used 
a range of different and inconstant criteria, some using 
International Working Group, or modifications thereof, 
and other study- specific criteria such as transfusion 
requirements. All these studies resulted in a final ESMO- 
MCSB v1.1 score of 2. In one of these studies108 QOL 
was evaluated and demonstrated to have improved but 
this was not reflected in grading since there is no QOL 
bonus for studies in which response rate is the primary 
outcome.
Shortcomings: The EHA working group identified one 
shortcoming derived from these evaluations:
1. In studies evaluating response rate as a primary end-
point, there is no provision of QOL bonus if improved 
QOL is demonstrated as a secondary outcome.
dIsCussIOn
The EHA with currently more than 5000 members is 
the largest European- based haematology association. In 
addition to its educational mission, it has a public policy 
and advocacy role that engages stakeholders, including 
patient representatives, to improve patient care and to 
raise awareness for haematology as a distinct medical 
discipline with specific needs.115 Reflecting these goals, 
EHA has observed the development of the ESMO- MCBS 
and its broad utility in solid tumour oncology with great 
interest, and in the absence of a value tool validated for 
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applicability of the ESMO- MCBS v1.1 as a first step to the 
development of a version validated for HMs.
There are several major differences in the behaviour 
of HMs as compared with solid tumour cancers. These 
differences arise largely from the more variable natural 
history of HMs which can range from fulminant (acute 
leukaemia and high- grade lymphomas) to almost benign 
(low- grade MDS). Furthermore, many of these malignant 
haematological diseases, even when they are not cured, 
they are characterised by very long PFS and OS that are 
rarely seen among incurable solid tumour malignancies. 
Finally, the endpoints used in the studies of treatments 
for HMs are sometimes different to those used in solid 
tumours and in some instances, such as CML, they are 
even disease- specific. Consequently, at the outset of this 
project we did not know if ESMO- MCBS v1.1 could be 
applied to studies in HMs, and if the grading of studies 
would generate grades considered reasonable by experts 
in the relevant diseases.
This evaluation of the behaviour of the ESMO- MCBS 
v1.1 in the grading of 80 studies across the full spectrum 
of HMs has demonstrated that the ESMO- MCBS v1.1 is 
widely applicable for the overwhelming majority of anal-
ysed studies (90% scoreable studies) and that the gener-
ated scores were generally adjudicated by clinical experts 
to reasonably accord with their evaluation of the magni-
tude of clinical benefit. In 5 of the 80 studies (6%), the 
ESMO- MCBS could not be applied at all21 27 46 49 50 78 and in 
3 more studies (4%), it could not be applied to one of the 
evaluable parameters.68 76 77 In the evaluation of imatinib 
in CML,36–38 it generated scores that were considered to 
under- represent the true value of the intervention in the 
opinion of experts in the evaluated diseases.
Based on the analysis of the scorability of studies and 
the reasonableness of the generated results, this field 
testing identified six shortcomings in the current version 
of the ESMO- MCBS that will require redress to improve 
the applicability and reasonableness of ESMO- MCBS 
scoring for malignant haematological conditions.
1. Regarding single- arm studies with curative intent, such 
as CAR T- cell salvage therapies, the ESMO- MCBS v1.1 
does not have a form to grade single- arm treatments 
with curative intent.
2. Regarding relatively indolent conditions with a very 
long PFS (or EFS) or OS such as CLL, CML, indolent 
lymphoma and MM, there is no mechanism to credit 
strong interim gains when the median of the control 
arm has not yet been reached.
3. The capitation of PFS at a maximal preliminary grade 
of 3, with provision for an upgrade based on tail of 
the curve only when there is a plateau in the arm with 
the study medication, may undervalue treatments with 
substantial late PFS gain but with no plateauing of the 
curves.
4. Regarding the standard molecular surrogate endpoints 
used for CML, the surrogacy of complete cytogenic re-
sponse and level 4–5 MMR must be acknowledged and 
incorporated.
5. The scale does not make provision for the grading of 
non- inferiority studies based on response rate criteria.
6. In studies evaluating response rate as a primary end-
point, there is no provision of QOL bonus if improved 
QOL is demonstrated as a secondary outcome.
Finally, it must be acknowledged that the results of the 
scale may not be reasonable for some of the least malig-
nant of the HMs such as low- risk MDS. Most of the studies 
for MDS were evaluated based on response rates, but there 
was heterogeneity of the available definitions of haemato-
logical response and their clinical meaningfulness. This 
underlines the need for a stand- alone form regarding 
studies with such heterogeneity in their response rates.
ESMO and the EHA are committed to the develop-
ment of a version of the ESMO- MCBS that is validated 
for HMs. Based on the findings of this study, a revised 
version of the ESMO- MCBS will be developed to address 
the identified shortcomings in the current version of the 
scale regarding the assessment of HMs. This develop-
ment process will incorporate all the usual stringencies 
for accountability of reasonableness that have character-
ised the development of the ESMO- MCBS. This, thus far, 
included field testing, statistical modelling, evaluation 
for reasonableness and openness to appeal and revision. 
Applying such a scale will support future decision- making 
and will provide insights that could be helpful in the 
design of future clinical trials.
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